ARGOM: Appendix 4 - Guidelines on OTC application for new ...

Information on the regulatory status of the new substance in other countries should be provided. If an application for approval has been rejected or withdrawn prior to approval, or withdrawn (e.g. due to adverse effects) following marketing approval, this should be noted in the application. ................
................